Real-World Use and Outcome of Ropeginterferon ALFA-2B in Polycythemia VERA Patients: A Multicenteric Study

被引：0
|
作者：
Pugliese, Novella [1 ,2 ]
Di Perna, Maria [3 ]
De Martino, Ugo [1 ,2 ]
Amico, Valeria [4 ]
Annunziata, Mario [5 ,6 ]
Martorelli, Maria Carmen [7 ]
Abagnale, Davide Pio [1 ]
Russo, Roberta [1 ]
Ferrentino, Maria [1 ]
Scarpa, Alessia [1 ]
Muriano, Francesco [1 ]
Martinelli, Vincenzo [1 ]
Pane, Fabrizio [1 ]
机构：
[1] Univ Naples Federico II, Div Hematol, Naples, Italy
[2] Univ Naples Federico II, SCT Unit, Naples, Italy
[3] A Tortora Hosp, Onco Hematol Unit, Pagani, Italy
[4] Immunoematol & Trasfus Azienda Ospedaliera San Pio, Benevento, Italy
[5] AORN Cardarelli, Div Hematol, Naples, Italy
[6] Cardarelli Hosp, Hematol Unit, Naples, Italy
[7] Univ Hosp San Giovanni Dio & Ruggi Aragona, Hematol & Transplant Ctr, Salerno, Italy
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-210785
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6651 / 6651
页数：1
相关论文
共 50 条
  • [21] A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera
    Jin, Jie
    Zhang, Lei
    Qin, Albert
    Wu, Daoxiang
    Shao, Zonghong
    Bai, Jie
    Chen, Suning
    Duan, Minghui
    Zhou, Hu
    Xu, Na
    Zhang, Sujiang
    Zuo, Xuelan
    Du, Xin
    Wang, Li
    Li, Pei
    Zhang, Xuhan
    Li, Yaning
    Zhang, Jingjing
    Wang, Wei
    Shen, Weihong
    Zagrijtschuk, Oleh
    Urbanski, Raymond
    Sato, Toshiaki
    Xiao, Zhijian
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
  • [22] Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study
    Yoko Edahiro
    Kohshi Ohishi
    Akihiko Gotoh
    Katsuto Takenaka
    Hirohiko Shibayama
    Takayuki Shimizu
    Kensuke Usuki
    Kazuya Shimoda
    Masafumi Ito
    Scott A. VanWart
    Oleh Zagrijtschuk
    Albert Qin
    Hiroaki Kawase
    Narihisa Miyachi
    Toshiaki Sato
    Norio Komatsu
    Keita Kirito
    International Journal of Hematology, 2022, 116 : 215 - 227
  • [23] Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study
    Edahiro, Yoko
    Ohishi, Kohshi
    Gotoh, Akihiko
    Takenaka, Katsuto
    Shibayama, Hirohiko
    Shimizu, Takayuki
    Usuki, Kensuke
    Shimoda, Kazuya
    Ito, Masafumi
    VanWart, Scott A.
    Zagrijtschuk, Oleh
    Qin, Albert
    Kawase, Hiroaki
    Miyachi, Narihisa
    Sato, Toshiaki
    Komatsu, Norio
    Kirito, Keita
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (02) : 215 - 227
  • [24] A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera
    Jie Jin
    Lei Zhang
    Albert Qin
    Daoxiang Wu
    Zonghong Shao
    Jie Bai
    Suning Chen
    Minghui Duan
    Hu Zhou
    Na Xu
    Sujiang Zhang
    Xuelan Zuo
    Xin Du
    Li Wang
    Pei Li
    Xuhan Zhang
    Yaning Li
    Jingjing Zhang
    Wei Wang
    Weihong Shen
    Oleh Zagrijtschuk
    Raymond Urbanski
    Toshiaki Sato
    Zhijian Xiao
    Experimental Hematology & Oncology, 12
  • [25] Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera - Final Phase I/II Peginvera Study Results
    Gisslinger, Heinz
    Buxhofer-Ausch, Veronika
    Thaler, Josef
    Forjan, Ernst
    Willenbacher, Ella
    Wolf, Dominik
    Kralovics, Robert
    Gisslinger, Bettina
    Stampfl-Mattersberger, Margarete
    Egle, Alexander
    Melchardt, Thomas
    Burgstaller, Sonja
    Schalling, Martin
    Krauth, Maria-Theresa
    Greil, Richard
    Kadlecova, Pavla
    Zoerer, Michael
    Empson, Victoria
    Grohmann-Izay, Barbara
    Klade, Christoph
    BLOOD, 2018, 132
  • [26] Hepatoid thymic carcinoma in a polycythemia vera patient treated with ropeginterferon Alfa-2b: Clinical, histopathological and molecular correlates
    Loscocco, Giuseppe G.
    Vannucchi, Margherita
    Santi, Raffaella
    Amorosi, Andrea
    Scarpino, Stefania
    Siciliano, Maria Chiara
    Guglielmelli, Paola
    Tripodo, Claudio
    Di Napoli, Arianna
    Vannucchi, Alessandro M.
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 263
  • [27] Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study
    Yoon, Seug Yun
    Yoon, Sung-Soo
    Yang, Deok-Hwan
    Lee, Gyeong-Won
    Sohn, Sang Kyun
    Shin, Ho-Jin
    Bae, Sung Hwa
    Choi, Chul Won
    Choi, Eun-Ji
    Cheong, June-Won
    Bang, Soo-Mee
    Park, Joon Seong
    Oh, Suk Joong
    Park, Yong
    Park, Young Hoon
    Lee, Sung-Eun
    INTERNATIONAL JOURNAL OF CANCER, 2025,
  • [28] Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study
    Yoko Edahiro
    Kohshi Ohishi
    Akihiko Gotoh
    Katsuto Takenaka
    Hirohiko Shibayama
    Takayuki Shimizu
    Kensuke Usuki
    Kazuya Shimoda
    Masafumi Ito
    Scott A. VanWart
    Oleh Zagrijtschuk
    Albert Qin
    Hiroaki Kawase
    Narihisa Miyachi
    Toshiaki Sato
    Norio Komatsu
    Keita Kirito
    International Journal of Hematology, 2022, 116 : 642 - 643
  • [29] Treatment with ropeginterferon alfa-2b in patients with hydroxyurea resistant or intolerant polycythemia vera in South Korea: one-year results from a phase 2 study
    Yoon, Seug Yun
    Lee, Sung-Eun
    BLOOD RESEARCH, 2024, 59 (01)
  • [30] Change in Polistemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials
    Gisslinger, Heinz
    TURKISH JOURNAL OF HEMATOLOGY, 2023, 40 (04) : 266 - 268
12345